



CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE WITH SUFFICIENT POSTAGE AS FIRST-CLASS MAIL IN AN ENVELOPE ADDRESSED TO:
COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450
ON: September 2, 2004

Maryse J. D'Ascola
ATTORNEY FOR APPLICANT

September 2, 2004
DATE

Attorney Docket No. P31220X2C2-R1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Leonard, et al. 02 September 2004

Serial No.: 10/024,858 Group Art Unit No.: 1615

Filed: December 18, 2001 Examiner: Humera Sheikh

For: "PAROXETINE CONTROLLED RELEASE COMPOSITIONS"

Commissioner for Patents
BOX RCE
P.O. Box 1450
Alexandria, VA 22313-1450

FILING OF AN INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §1.97(b) AND 37 C.F.R. §1.114(c)


The attached list of citations on PTO Form 1449 is being submitted under the provisions of 37 CFR §1.56 and §1.97 for consideration by the United States Patent and Trademark Office prior to the granting of this patent. Their inclusion herein should not, however, be construed as an admission that any particular cited document is effective prior art or that it discloses or renders obvious any aspect of the claimed invention. A copy of each cited document is enclosed, except for those documents which are already part of the filewrapper. This statement is being filed within the time period specified in 37 CFR §1.97(b). No fee is required.

This application was allowed at the time of filing an RCE concurrent with this IDS. The corresponding European application granted as European patent No. EP 0 839 039 B1, on November 5, 2003. European patent No. EP 0 839 039 B1, with 7 granted claims, is enclosed herewith as Reference BF. On August 4 and on August 5, 2004 oppositions were filed in the matter of European patent No. EP 0 839 039 B1.

Serial No.: 10/024,858
Group Art Unit No.: 1615

This Information Disclosure Statement contains the opposition papers, and the documents cited in the oppositions that are not already part of the filewrapper. This Information Disclosure Statement is intended to alert the United States Patent and Trademark Office to the existence of the oppositions in the corresponding European patent. Applicants contend that the currently pending claims are allowable over the enclosed documents.

Respectfully submitted,


Wayne J. Dustman
Attorney for Applicants
Registration No. 33,870

GLAXOSMITHKLINE
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-5023
Facsimile (610) 270-5090

N:\wjd\paroxetine\P31220x2c2oppidsletter.doc

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office		ATTY. DOCKET NO. P31220X2C2-R1	SERIAL NO. 10/024,858
INFORMATION DISCLOSURE STATEMENT BY APPLICANT SEP 07 2004 <i>(Use several sheets if necessary)</i>		APPLICANT Leonard, et al.			
		FILING DATE December 18, 2001	GROUP 1615		

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	AF	5, 322, 697	06/21/1994	Meyers			
	AG	5, 284, 662	02/08/1994	Koparkar, et al.			
	AH	4, 851, 228	07/25/1989	Zentner, et al.			

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation Yes	No
	BF	0 839 039	05.11.2003	EP				
	BG	0 546 593	23.10.1992	EP				
	BH	WO 92/19226	12.11.1992	WIPO				
	BI	WO 93/24154	09.12.1993	WIPO				
	BJ	0 654 263	17.11.94	EP				

OTHER DOCUMENTS (*Including Author, Title, Date, Pertinent Pages, Etc.*)

CG	Opposition to European Patent No. EP 0839039, (Aug. 5, 2004) by Solvay Pharmaceuticals, Netherlands.
CH	Opposition to European Patent No. EP 0839039. (Aug. 4, 2004) by Dragotti & Associati SRL, Italy.
CI	Aulton, Ed., "Pharmaceutics: The Science of Dosage form Design", pp 204-211, Churchill Livingstone, Edinburgh (1988)
CJ	Leonard; <i>J Clin Psychiatry</i> , 1993 Aug; 54 Suppl: 3-15; discussion.
CK	Leonard: <i>Drugs</i> 1992; 43 Suppl 2:3-9; discussion 9-10.
CL	Jenner ; <i>Int Clin Psychopharmacol</i> . 1992 Jun; 6 Suppl 4: pp. 69-80.
CM	De Wilde et al., <i>Acta Psychiatr Scand</i> . 1993 Feb; 87(2): pp. 141-5.
CN	Boyer & Feighner; <i>J Clin Psychiatry</i> , 1992 Feb; 53 Suppl: pp. 3-6.
CO	Dechant & Clissold; <i>Drugs</i> 1991 Feb; 41(2): pp. 225-53.
CP	Lucchelli et al., <i>Br J Pharmacol</i> ., 1995 Mar; 114(5): pp. 1017-25.
CQ	Sanger & McClelland ; <i>Eur J Pharmacol</i> . 1986 Aug 15; 127(3): pp. 179-85.
CR	Chambliss et al., <i>J Pharma Sci</i> . 1984 Sep; 73(9): pp. 1215-9.
CS	Ryan et al., <i>Clin Pharmacol Ther</i> . 1987 Jul; 42(1): pp. 28-32.
CT	Hawthorne et al., <i>Br J Clin Pharmacol</i> . 1991 Jul; 32(1): pp. 77-83.
CU	Aabakken et al., <i>Scand J Gastroenterol Suppl</i> . 1989; 163: pp. 65-73.
CV	Florence & Jani ; <i>Drug Saf</i> . 1994 Mar; 10(3): pp. 233-66.
CW	Mori et al., <i>J Pharm Sci</i> 1991 Sep; 80(9): pp. 876-80.
CX	Lucker et al., <i>Arzneimittelforschung</i> . 1982; 32(4): pp. 409-13.



Form PTO-1449 BASIC INFORMATION & PAPERWORK REDUCTION ACT OFFICE OF THE SECRETARY	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. P31220X2C2-R1	SERIAL NO. 10/024,858
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>		APPLICANT Leonard, et al.	
		FILING DATE December 18, 2001	GROUP 1615

OTHER DOCUMENTS, CONT. (Including Author, Title, Date, Pertinent Pages, Etc.)

CY	Fara et al., Pharm Res. 1988 Mar; 5(3): pp. 165-71.
CZ	Perucca et al, Clin Pharmacokinet (1994) 27(3): pp.175-190.
CAA	ABPI Data Sheet Compendium 1988-89, pp. 445-6.
CAB	Freeman, J Psychiatr Neurosci, vol 16 no 2 (Suppl 1), 1991
EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copyof this form with next communication to applicant.

n:\wjd\paroxetine\p31220x2c2-r1-pt01449.doc